Intensity Therapeutics, Inc. (INTS) Stock

Intensity Therapeutics, Inc., a pioneering clinical-stage biotechnology firm headquartered in Westport, Connecticut, specializes in the discovery, development, and commercialization of innovative cancer therapies targeting solid tumors. At the forefront of its portfolio is INT230-6, the company's leading product candidate currently undergoing Phase 2 clinical trials. INT230-6 shows promise in treating a spectrum of challenging refractory solid tumors, including pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers.

In its commitment to advancing cancer treatment paradigms, Intensity Therapeutics has forged strategic collaborations with industry leaders. These include partnerships with Merck Sharpe & Dohme Corp. to explore combining INT230-6 with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Additionally, collaborations with Bristol-Myers Squibb Company focus on evaluating INT230-6 alongside Yervoy for advanced liver, breast, and sarcoma cancers. Furthermore, the company collaborates with Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a pivotal neoadjuvant Phase II trial for early-stage breast cancer patients.

Founded in 2012, Intensity Therapeutics continues to drive innovation in cancer therapeutics. By leveraging its deep scientific expertise and strategic collaborations, the company strives to deliver transformative treatments that address critical unmet needs in oncology, offering new hope to patients worldwide.